Overview

European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients

Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Bellus Health Inc
Treatments:
Tramiprosate